About Motus GI
Motus GI Holdings, Inc. is a medical technology company dedicated to improving endoscopy outcomes and experiences.
CEO: Mark Pomeranz
CFO: Andrew Taylor
37 articles with Motus GI
Motus GI Holdings, Inc.,, a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, reported its financial results for the second quarter ended June 30, 2019 and provided a corporate update.
EU issued patent strengthens Company’s intellectual property estate and supports future international expansion opportunities for the Pure-Vu® System
Motus GI Holdings, Inc. announced the pricing of its underwritten registered public offering of 6,666,667 shares of its common stock, offered at a price to the public of $3.00 per share for expected gross proceeds of $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
Motus GI Holdings, Inc. announced that it has commenced an underwritten public offering of its common stock.
Motus GI Bolsters Commercial and Quality/Regulatory Expertise with Two Key Senior Management Additions
Purposefully built Management Team to drive commercial launch of Pure-Vu® GEN2 in the U.S. hospital market
Presentation with live audio webcast on Wednesday, June 19th at 10:30 AM ET
FDA clearance marks key regulatory milestone and advances commercial strategy for launch in U.S. hospital market in 2019
Presentation with live audio webcast Wednesday, May 22nd at 4:30 PM PT
Motus GI Holdings, Inc. reported its financial results for the quarter ended March 31, 2019 and provided a corporate update.
Motus GI to Present Clinical Results from REDUCE Study Evaluating the Pure-Vu® System at Digestive Disease Week® 2019
Motus GI Holdings, Inc. announced that full clinical results from the Company’s REDUCE study evaluating the Pure-Vu® System will be presented at Digestive Disease Week® 2019, being held May 18 - 21, 2019 in San Diego, CA.
2018 marked by strengthening of executive team, expansion of commercial organization, bolstering of clinical and health economic data, and achievement of important regulatory milestones
Motus GI Holdings, Inc. announced that Tim Moran, Chief Executive Officer, will present a company overview and update at Oppenheimer’s 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 2:45 PM ET in New York, NY.
Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology
Pure-Vu® System found to be simple, safe and effective in cleansing inadequately prepared colons during a colonoscopy achieving a 98% success rate in patients that had minimal bowel preparation
Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal
Published data show significant increase in the number of subjects with an adequate cleansing level to 100% from 19.1% at baseline after use of the Pure-Vu® System
Presentation with live audio webcast Tuesday, January 8, 2019 at 4:00 PM PST
Motus GI Holdings, Inc., announced the pricing of its follow-on public offering of 5,000,000 shares of its common stock at a price of $2.70 per share, for total gross proceeds of $13.5 million.
Motus GI Holdings, Inc., announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of 5,000,000 shares of its common stock.
Ongoing market development programs continue to build foundation for full commercial launch of the Pure-Vu® System in 2019
Pure-Vu® Slim Sleeve provides broader procedural access to cover a full range of colonoscopes
Motus GI Presents Positive Clinical Data from U.S. Prospective Study of the Pure-Vu® System at the 2018 American College of Gastroenterology (ACG) Annual Meeting
Data demonstrates safety and effectiveness of the Pure-Vu® System in patients who had minimal preparation regimens and who were allowed to consume solid food the day before the procedure